Cetrelimab

• CAT Number: I042141
• CAS Number: 2050478-92-5
• Purity: ≥95%

Cetrelimab（Cat No.:I042141）is an investigational monoclonal antibody that targets PD-1 (programmed cell death protein 1), an immune checkpoint receptor found on T-cells. PD-1 suppresses immune responses, enabling cancer cells to evade detection by the immune system. By inhibiting PD-1, cetrelimab aims to restore T-cell activity and enhance the immune system’s ability to recognize and attack cancer cells. It is being studied in clinical trials for its potential to treat various cancers, including melanoma, non-small cell lung cancer (NSCLC), and other solid tumors, with the goal of improving patient outcomes through immune system activation.